Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: A subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter-Reference-Cited by-同舟云学术

Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: A subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter

Published:2014-08-04 Issue:1 Volume:69 Page:34-42
ISSN:1323-1316
Container-title:Psychiatry and Clinical Neurosciences
language:en
Short-container-title:Psychiatry Clin Neurosci

Author:

Ozaki Norio¹,Otsubo Tempei²,Kato Masaki³,Higuchi Teruhiko⁴,Ono Hiroaki⁵,Kamijima Kunitoshi⁶,

Affiliation:

1. Department of Psychiatry; Nagoya University Graduate School of Medicine; Nagoya Japan

2. Department of Psychiatry and Psychosomatic Medicine; Tokyo Shinjuku Medical Center; Tokyo Japan

3. Department of Neuropsychiatry; Kansai Medical University; Osaka Japan

4. National Center of Neurology and Psychiatry; Tokyo Japan

5. Otsuka Pharmaceutical Co., Ltd; Tokyo Japan

6. International University of Health and Welfare; Otawara Japan

Publisher

Wiley

Subject

Psychiatry and Mental health,Clinical Neurology,Neurology,General Medicine,General Neuroscience

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/pcn.12214/fullpdf

Reference24 articles.

1. World Health Organization 2012 http://www.who.int/mediacentre/factsheets/fs369/en/

2. Global burden of disease attributable to mental and substance use disorders: Findings from the Global Burden of Disease Study;Whiteford;Lancet,2013

3. Diagnosis and definition of treatment-resistant depression;Fava;Biol. Psychiatry,2003

4. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report;Rush;Am. J. Psychiatry,2006

5. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III;Lam;Pharmacotherapy. J. Affect. Disord.,2009

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trends and off-label utilization of antipsychotics in children and adolescents from 2016 to 2021 in China: a real-world study;Child and Adolescent Psychiatry and Mental Health;2024-06-21

2. The Potential Role of Aripiprazole Augmentation for Major Depressive Disorder with Anxious Distress in Naturalistic Treatment Setting;Clinical Psychopharmacology and Neuroscience;2024-02-04

3. Atypical antipsychotics in the treatment of depression in affective disorders and schizophrenia (using the aripiprazole model);S.S. Korsakov Journal of Neurology and Psychiatry;2024

4. Use of the Third-Generation Atypical Antipsychotic Aripiprazole (Zylaxera®) for Treatment of Depressive States in Schizophrenia: Efficacy and Safety Study;Psikhiatriya;2023-06-19

5. Efficacy of adjunctive brexpiprazole on symptom clusters of major depressive disorder: A post hoc analysis of four clinical studies;Journal of Affective Disorders;2022-11